Helus Pharma Surpasses Milestones in Phase 3 Study for Depression Treatment HLP003

Helus Pharma Milestone: Enrollment Achieved Ahead of Schedule in Phase 3 Study for Major Depressive Disorder

In a significant advancement for mental health treatment, Helus Pharma has announced the swift completion of participant enrollment in its APPROACH Phase 3 pivotal study of HLP003. This investigational treatment aims to provide an adjunctive solution for patients suffering from Major Depressive Disorder (MDD), particularly those who have not found relief through standard antidepressant therapies. The study marks a crucial milestone for the company and the global fight against depression.

HLP003 is a novel serotonergic agonist, designed to specifically target serotonin pathways that promote neuroplasticity, enhancing the potential for recovery in patients. The decision to proceed with such an ambitious study was rooted in the well-documented challenges faced by individuals dealing with moderate to severe MDD. Despite the availability of various antidepressants, many patients remain inadequately treated, leading to the need for innovative approaches.

The Phase 3 APPROACH study has successfully enrolled 223 adult participants, all of whom have exhibited inadequate responses to stable doses of other antidepressants. Participants in the study will be randomized to receive either HLP003 or a placebo, with the treatment regimen including two doses administered three weeks apart. This design is set to assess the primary endpoint focused on the change in the Montgomery-Asberg Depression Rating Scale (MADRS) scores after six weeks, with secondary assessments extending to twelve weeks post-treatment.

This progress is not merely a reflection of Helus Pharma’s operational efficiency but also highlights the pressing needs within the mental health sector. Current first-line treatments insufficiently address the complexities of MDD in a significant number of patients. Traditional adjunct options, like atypical antipsychotics, can introduce additional side effects such as weight gain and sedation, which often hinder long-term treatment adherence. HLP003 aims to overcome these obstacles by offering a more effective and patient-friendly alternative.

Eric So, the Interim CEO of Helus Pharma, expressed gratitude toward the clinical team and trial participants for achieving this milestone ahead of schedule. He emphasized that the expedited enrollment reflects the robust processes of participant screening and site selection, ensuring a study population representative of those affected by moderate to severe MDD.

The announcement also bodes well for the anticipated topline data release scheduled for the fourth quarter of 2026. Participants from the APPROACH study are also eligible to transition into the EMBRACE study, the second pivotal study within the Phase 3 PARADIGM Program. This continuity not only furthers research prospects but also facilitates the collection of long-term safety and efficacy data.

Johnson & Johnson’s recent report detailing substantial sales growth of SPRAVATO®, a different treatment for resistant depression, underscores the increasing recognition and demand for novel therapies within the mental health landscape. As Helus Pharma advances its critical studies, it's clear that HLP003 could have significant implications not only for those suffering from MDD but also for the broader mental health treatment paradigm.

Additionally, the ongoing EMBRACE study is designed to evaluate further the efficacy and safety of HLP003, with the possibility for rollover participants from both APPROACH and EMBRACE to join the long-term EXTEND study. This comprehensive approach ensures a deeper investigation into the durability of treatment and the potential for redosing strategies to maintain therapeutic effects.

Moreover, Helus Pharma's commitment to developing a strong intellectual property portfolio, with over 350 patent applications and 100 patents granted worldwide, demonstrates its dedication to delivering novel serotonergic agents to meet the pressing needs of mental health patients. The company's focus on innovation underscores its broader mission to enhance the landscape of psychiatric care through effective and sustainable treatment solutions.

In summary, Helus Pharma's advancements with HLP003 bring renewed hope for individuals suffering from Major Depressive Disorder. As clinical studies progress, the pharmaceutical landscape may witness a transformative shift, providing patients with accessible, effective, and practical treatment options. The full data readout and subsequent developments in the clinical pipeline will be keenly observed, as the industry eagerly anticipates the impact of these findings on future therapeutic approaches.

For more information on Helus Pharma and updates regarding their innovative treatment solutions, visit www.helus.com